Peritoneovenous shunting for refractory ascites results in worsening of nephrotic syndrome

Akinobu Takaki, Yohei Maeshima, Takahito Yagi, Akihiro Katayama, Norikazu Hinamoto, Shigeru Akagi, Hitoshi Sugiyama, Takeshi Tomoda, Yoshiaki Iwasaki, Tetsuya Yasunaka, Fusao Ikeda, Yasuhiro Miyake, Haruhiko Kobashi, Atsushi Hirano, Hirofumi Makino, Kazuhide Yamamoto

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Peritoneovenous shunt (PVS) is accepted as a treatment for refractory ascites due to liver cirrhosis. Infection is a well-known complication of shunting. However, the effects of PVS in terms of complications for renal disease are unclear. We encountered a case involving a 52-year-old man with alcoholic liver cirrhosis and complications of nephrotic syndrome that were worsened by PVS. He received PVS for refractory ascites due to alcoholic liver cirrhosis before coming to our hospital for evaluation for liver transplantation. Nephrotic syndrome was then identified due to cirrhosis-related membranoproliferative glomerulonephritis (MPGN). Prednisolone was administrated at 60mg/day for MPGN. On day 5, he showed grade IV hepatic encephalopathy (West Haven criteria). Tapering prednisolone and intestinal cleansing with lactulose treatment improved hepatic encephalopathy, but hyperammonemia persisted and the PVS was removed. After shunt removal, urinary protein levels decreased from 4-6g/day to 0.3-0.5g/day and ammonia levels decreased. PVS may increase the excretion of urinary protein and increase ammonia levels in patients with complications of glomerulonephritis.

Original languageEnglish
Pages (from-to)1048-1053
Number of pages6
JournalHepatology Research
Volume42
Issue number10
DOIs
Publication statusPublished - Oct 2012

Fingerprint

Peritoneovenous Shunt
Nephrotic Syndrome
Ascites
Membranoproliferative Glomerulonephritis
Alcoholic Liver Cirrhosis
Hepatic Encephalopathy
Prednisolone
Ammonia
Hyperammonemia
Lactulose
Glomerulonephritis
Liver Cirrhosis
Liver Transplantation
Proteins
Fibrosis
Kidney
Therapeutics
Infection

Keywords

  • Liver cirrhosis
  • Nephrotic syndrome
  • Peritoneovenous shunt

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases

Cite this

Peritoneovenous shunting for refractory ascites results in worsening of nephrotic syndrome. / Takaki, Akinobu; Maeshima, Yohei; Yagi, Takahito; Katayama, Akihiro; Hinamoto, Norikazu; Akagi, Shigeru; Sugiyama, Hitoshi; Tomoda, Takeshi; Iwasaki, Yoshiaki; Yasunaka, Tetsuya; Ikeda, Fusao; Miyake, Yasuhiro; Kobashi, Haruhiko; Hirano, Atsushi; Makino, Hirofumi; Yamamoto, Kazuhide.

In: Hepatology Research, Vol. 42, No. 10, 10.2012, p. 1048-1053.

Research output: Contribution to journalArticle

Takaki, Akinobu ; Maeshima, Yohei ; Yagi, Takahito ; Katayama, Akihiro ; Hinamoto, Norikazu ; Akagi, Shigeru ; Sugiyama, Hitoshi ; Tomoda, Takeshi ; Iwasaki, Yoshiaki ; Yasunaka, Tetsuya ; Ikeda, Fusao ; Miyake, Yasuhiro ; Kobashi, Haruhiko ; Hirano, Atsushi ; Makino, Hirofumi ; Yamamoto, Kazuhide. / Peritoneovenous shunting for refractory ascites results in worsening of nephrotic syndrome. In: Hepatology Research. 2012 ; Vol. 42, No. 10. pp. 1048-1053.
@article{53c4f3c8f3424cb0b72d058c5be97e22,
title = "Peritoneovenous shunting for refractory ascites results in worsening of nephrotic syndrome",
abstract = "Peritoneovenous shunt (PVS) is accepted as a treatment for refractory ascites due to liver cirrhosis. Infection is a well-known complication of shunting. However, the effects of PVS in terms of complications for renal disease are unclear. We encountered a case involving a 52-year-old man with alcoholic liver cirrhosis and complications of nephrotic syndrome that were worsened by PVS. He received PVS for refractory ascites due to alcoholic liver cirrhosis before coming to our hospital for evaluation for liver transplantation. Nephrotic syndrome was then identified due to cirrhosis-related membranoproliferative glomerulonephritis (MPGN). Prednisolone was administrated at 60mg/day for MPGN. On day 5, he showed grade IV hepatic encephalopathy (West Haven criteria). Tapering prednisolone and intestinal cleansing with lactulose treatment improved hepatic encephalopathy, but hyperammonemia persisted and the PVS was removed. After shunt removal, urinary protein levels decreased from 4-6g/day to 0.3-0.5g/day and ammonia levels decreased. PVS may increase the excretion of urinary protein and increase ammonia levels in patients with complications of glomerulonephritis.",
keywords = "Liver cirrhosis, Nephrotic syndrome, Peritoneovenous shunt",
author = "Akinobu Takaki and Yohei Maeshima and Takahito Yagi and Akihiro Katayama and Norikazu Hinamoto and Shigeru Akagi and Hitoshi Sugiyama and Takeshi Tomoda and Yoshiaki Iwasaki and Tetsuya Yasunaka and Fusao Ikeda and Yasuhiro Miyake and Haruhiko Kobashi and Atsushi Hirano and Hirofumi Makino and Kazuhide Yamamoto",
year = "2012",
month = "10",
doi = "10.1111/j.1872-034X.2012.01012.x",
language = "English",
volume = "42",
pages = "1048--1053",
journal = "Hepatology Research",
issn = "1386-6346",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Peritoneovenous shunting for refractory ascites results in worsening of nephrotic syndrome

AU - Takaki, Akinobu

AU - Maeshima, Yohei

AU - Yagi, Takahito

AU - Katayama, Akihiro

AU - Hinamoto, Norikazu

AU - Akagi, Shigeru

AU - Sugiyama, Hitoshi

AU - Tomoda, Takeshi

AU - Iwasaki, Yoshiaki

AU - Yasunaka, Tetsuya

AU - Ikeda, Fusao

AU - Miyake, Yasuhiro

AU - Kobashi, Haruhiko

AU - Hirano, Atsushi

AU - Makino, Hirofumi

AU - Yamamoto, Kazuhide

PY - 2012/10

Y1 - 2012/10

N2 - Peritoneovenous shunt (PVS) is accepted as a treatment for refractory ascites due to liver cirrhosis. Infection is a well-known complication of shunting. However, the effects of PVS in terms of complications for renal disease are unclear. We encountered a case involving a 52-year-old man with alcoholic liver cirrhosis and complications of nephrotic syndrome that were worsened by PVS. He received PVS for refractory ascites due to alcoholic liver cirrhosis before coming to our hospital for evaluation for liver transplantation. Nephrotic syndrome was then identified due to cirrhosis-related membranoproliferative glomerulonephritis (MPGN). Prednisolone was administrated at 60mg/day for MPGN. On day 5, he showed grade IV hepatic encephalopathy (West Haven criteria). Tapering prednisolone and intestinal cleansing with lactulose treatment improved hepatic encephalopathy, but hyperammonemia persisted and the PVS was removed. After shunt removal, urinary protein levels decreased from 4-6g/day to 0.3-0.5g/day and ammonia levels decreased. PVS may increase the excretion of urinary protein and increase ammonia levels in patients with complications of glomerulonephritis.

AB - Peritoneovenous shunt (PVS) is accepted as a treatment for refractory ascites due to liver cirrhosis. Infection is a well-known complication of shunting. However, the effects of PVS in terms of complications for renal disease are unclear. We encountered a case involving a 52-year-old man with alcoholic liver cirrhosis and complications of nephrotic syndrome that were worsened by PVS. He received PVS for refractory ascites due to alcoholic liver cirrhosis before coming to our hospital for evaluation for liver transplantation. Nephrotic syndrome was then identified due to cirrhosis-related membranoproliferative glomerulonephritis (MPGN). Prednisolone was administrated at 60mg/day for MPGN. On day 5, he showed grade IV hepatic encephalopathy (West Haven criteria). Tapering prednisolone and intestinal cleansing with lactulose treatment improved hepatic encephalopathy, but hyperammonemia persisted and the PVS was removed. After shunt removal, urinary protein levels decreased from 4-6g/day to 0.3-0.5g/day and ammonia levels decreased. PVS may increase the excretion of urinary protein and increase ammonia levels in patients with complications of glomerulonephritis.

KW - Liver cirrhosis

KW - Nephrotic syndrome

KW - Peritoneovenous shunt

UR - http://www.scopus.com/inward/record.url?scp=84866757800&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84866757800&partnerID=8YFLogxK

U2 - 10.1111/j.1872-034X.2012.01012.x

DO - 10.1111/j.1872-034X.2012.01012.x

M3 - Article

VL - 42

SP - 1048

EP - 1053

JO - Hepatology Research

JF - Hepatology Research

SN - 1386-6346

IS - 10

ER -